Yamauchi Paul
a Dermatology Institute and Skin Care Center , Santa Monica , CA , USA.
b Division of Dermatology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
Expert Rev Clin Immunol. 2017 Feb;13(2):85-91. doi: 10.1080/1744666X.2017.1270756. Epub 2016 Dec 21.
Betamethasone dipropionate has been used for the topical treatment of psoriasis in multiple formulations. DFD-01 (Sernivo™, Promius Pharma LLC) is a new midpotent lotion formulation of betamethasone dipropionate 0.05% that has recently been approved for the treatment of mild to moderate psoriasis for up to 4 weeks. Areas covered: This review will critically appraise available clinical information on DFD-01. Phase 3 efficacy and safety results will be reviewed on head-to-head comparison of DFD-01 with a superpotent augmented betamethasone dipropionate 0.05% lotion. It is suggested that the formulation of DFD-01 has enabled this midpotent topical steroid to demonstrate equivalent efficacy to a superpotent steroid. Expert commentary: DFD-01's unique advantage is that this product has the efficacy of a higher potency steroid but with the safety profile of a mid-potency steroid based on VCA assays. This formulation also has aesthetic appeal, which may benefit compliance.
丙酸倍他米松已被用于多种剂型的银屑病局部治疗。DFD - 01（Sernivo™，Promius制药有限责任公司）是一种新型的中效洗剂剂型，含有0.05%的丙酸倍他米松，最近已被批准用于治疗轻度至中度银屑病，最长疗程为4周。涵盖领域：本综述将严格评估关于DFD - 01的现有临床信息。将对DFD - 01与0.05%超强效丙酸倍他米松洗剂进行头对头比较的3期疗效和安全性结果进行综述。有人认为，DFD - 01的剂型使这种中效局部类固醇能够展现出与超强效类固醇相当的疗效。专家评论：DFD - 01的独特优势在于，基于VCA检测，该产品具有高效能类固醇的疗效，但具备中效能类固醇的安全性。这种剂型还具有美学吸引力，这可能有利于提高依从性。
